Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04365374 · ClinicalTrials.gov registry record · Phase 3

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

A Phase 3 study of Brain Metastases, sponsored by GT Medical Technologies.

Active
Registry status
Phase 3
Development phase
230
Enrollment target
20
Study locations

NCT04365374: Active Phase 3 study of Brain Metastases, sponsored by GT Medical Technologies.

NCT04365374 is a Phase 3 study of Brain Metastases that is active but no longer recruiting, run by GT Medical Technologies. The registered enrollment target is 230 participants, above the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04365374, a Phase 3 study of Brain Metastases, is active but no longer recruiting, sponsored by GT Medical Technologies.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
230 participants
Enrollment target
20
Study locations

Study Summary

This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.

Primary Outcome

Surgical bed control is defined as the absence of new nodular contrast enhancement in the index lesion surgical bed.

Conditions Studied

Interventions

  • RADIATION Stereotactic Radiation Therapy
  • DEVICE Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)

Study Locations (20)

Florida

  • Ascension St. Vincent's- Riverside - Jacksonville
  • Baptist MD Anderson Cancer Center- Jacksonville - Jacksonville
  • HCA Florida First Coast Neurology- Orange Park - Orange Park
  • Advent health Orlando - Orlando
  • Orlando Health - Orlando
  • Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital - Tampa

Georgia

  • Piedmont Hospital - Atlanta
  • Winship Cancer Institute of Emory University - Atlanta

Minnesota

  • Abbott Northwestern Hospital - Minneapolis
  • University Of Minnesota - Minneapolis

Missouri

  • Ellis Fischel Cancer Center at University of Missouri - Columbia
  • SSM Health Saint Louis University Hospital - St Louis

Arizona

  • HonorHeath Scottsdale Osborn Medical Center - Phoenix

Arkansas

  • University of Arkansas Medical Center - Little Rock

Illinois

  • RUSH University - Chicago

Indiana

  • Indiana University, IU Health Methodist Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2021-04-06
Est. Completion 2029-08-30
Phase Phase 3
GT Medical Technologies

4 total trials

What the registry record for NCT04365374 still lists

NCT04365374 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (10% higher).

The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Radiation Therapy is the first listed.

NCT04365374 names 20 study sites across 12 states, led by Florida, Georgia, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04365374 about?

NCT04365374 is a clinical study titled "Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)". This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.

What is the current status of trial NCT04365374?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2021-04-06. Estimated completion is 2029-08-30.

What conditions does trial NCT04365374 study?

This clinical trial studies the following conditions: Brain Metastases.

What interventions are being tested in trial NCT04365374?

The interventions under investigation include: Stereotactic Radiation Therapy (RADIATION), Gamma Tile-Surgically Targeted Radiation Therapy (STaRT) (DEVICE).

Who is sponsoring clinical trial NCT04365374?

This trial is sponsored by GT Medical Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04365374 being conducted?

This trial has 20 study locations across Arizona, Arkansas, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Metastases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04365374's enrollment target sits among peer trials

230 4th of 67 higher than 64 of 67 other Brain Metastases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04365374, the US trial registry maintained by the National Library of Medicine. NCT04365374 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.